Volume 11, Issue 4 (11-2025)
Journal of Research in Applied and Basic Medical Sciences 2025, 11(4): 377-382 |
Back to browse issues page
Ethics code: MU/Research/EC/Ph.D./2021/93a 23.11.2021
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Singh Rathore R, Vishwe A, Kumar S, Sharma L, Bansal A, jakhar P. Drug Utilization Patterns in Type 2 Diabetes Mellitus: A Hospital-Based Observational Study in Central India. Journal of Research in Applied and Basic Medical Sciences 2025; 11 (4) :377-382
URL: http://ijrabms.umsu.ac.ir/article-1-444-en.html
URL: http://ijrabms.umsu.ac.ir/article-1-444-en.html
Rajveer Singh Rathore * 
, Akash Vishwe , Susheel Kumar , Lokendra Sharma , Alka Bansal , Punam Jakhar
, Akash Vishwe , Susheel Kumar , Lokendra Sharma , Alka Bansal , Punam Jakhar
Department of Pharmacology, Index Medical College Hospital and Research Centre, Indore , rsr3579@gmail.com
Abstract: (90 Views)
Background:
Type 2 Diabetes Mellitus poses a major challenge to the Indian healthcare system due to its rising prevalence, early onset, and long-term pharmacological requirements. Evaluating drug utilization patterns is essential to promote rational prescribing, improve glycemic control, and ensure adherence to the guidelines. The study aimed to evaluate prescribing patterns of antidiabetic drugs in type 2 diabetes mellitus patients at a tertiary care center in Central India.
Methods:
A prospective exploratory study was conducted from January 2022 to December 2024 at Index Medical College, Indore, including 964 type 2 diabetes mellitus patients aged ≥ 20 years attending opd. demographic details, comorbidities, and prescription data were collected using a structured case report form. Statistical analysis was performed using SPSS version 30, applying descriptive statistics and inferential tests (Chi-square, Pearson’s correlation, and ANOVA), with p < 0.05 considered statistically significant.
Results:
The mean age of patients was 46.91 ± 12.42 years, with significant male predominance (56.33%, p = 0.002); most patients belonged to the 41–50-year age group (32.57%). Metformin was the most commonly prescribed drug (48.03%), followed by glimepiride (36.41%), sitagliptin (17.43%), and dapagliflozin (13.07%). Combination therapy was more frequent (66.29%) than monotherapy (33.71%). The most common fixed-dose combination was metformin with glimepiride (15.98%). Polypharmacy (≥5 drugs) was observed in 34% of patients and was significantly associated with hypertension (11.31%, p < 0.0001) and dyslipidemia (6.95%). A strong positive correlation was noted between BMI and HbA1c (r = 0.997, p = 0.003), with significantly higher HbA1c levels in obese patients (p < 0.001).
Conclusion:
The study indicates a predominant use of metformin-based combination regimens in line with standard treatment protocols. The high prevalence of polypharmacy and its association with comorbidities highlights the need for regular prescription audits and individualized therapy to ensure rational drug use and improved patient outcomes.
Type 2 Diabetes Mellitus poses a major challenge to the Indian healthcare system due to its rising prevalence, early onset, and long-term pharmacological requirements. Evaluating drug utilization patterns is essential to promote rational prescribing, improve glycemic control, and ensure adherence to the guidelines. The study aimed to evaluate prescribing patterns of antidiabetic drugs in type 2 diabetes mellitus patients at a tertiary care center in Central India.
Methods:
A prospective exploratory study was conducted from January 2022 to December 2024 at Index Medical College, Indore, including 964 type 2 diabetes mellitus patients aged ≥ 20 years attending opd. demographic details, comorbidities, and prescription data were collected using a structured case report form. Statistical analysis was performed using SPSS version 30, applying descriptive statistics and inferential tests (Chi-square, Pearson’s correlation, and ANOVA), with p < 0.05 considered statistically significant.
Results:
The mean age of patients was 46.91 ± 12.42 years, with significant male predominance (56.33%, p = 0.002); most patients belonged to the 41–50-year age group (32.57%). Metformin was the most commonly prescribed drug (48.03%), followed by glimepiride (36.41%), sitagliptin (17.43%), and dapagliflozin (13.07%). Combination therapy was more frequent (66.29%) than monotherapy (33.71%). The most common fixed-dose combination was metformin with glimepiride (15.98%). Polypharmacy (≥5 drugs) was observed in 34% of patients and was significantly associated with hypertension (11.31%, p < 0.0001) and dyslipidemia (6.95%). A strong positive correlation was noted between BMI and HbA1c (r = 0.997, p = 0.003), with significantly higher HbA1c levels in obese patients (p < 0.001).
Conclusion:
The study indicates a predominant use of metformin-based combination regimens in line with standard treatment protocols. The high prevalence of polypharmacy and its association with comorbidities highlights the need for regular prescription audits and individualized therapy to ensure rational drug use and improved patient outcomes.
Keywords: Combination therapy, Drug utilization, Metformin, Polypharmacy, Prescribing patterns, Type 2 diabetes mellitus
Type of Study: orginal article |
Subject:
Other
References
1. Das AK, Dutta A, Maitiy A, Sarkar D, Nandy M, Ghosh J. Prescribing pattern of antidiabetic drugs in type 2 diabetes mellitus at a tertiary care hospital in Eastern India. International Journal of Community Medicine and Public Health. 2021;8(2):721-72. doi: 10.18203/2394-6040.ijcmph20210228 [DOI:10.18203/2394-6040.ijcmph20210228]
2. Parikh RM, Saboo B, Misra A, Basit A, Aravind S, Bhowmik B, et al. Clinical Research & Reviews. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2025;19:103205. doi: 10.1016/j.dsx.2025.103205 [DOI:10.1016/j.dsx.2025.103205] [PMID] [PMCID]
3. Acharya SK, Naringrekar S, Patel KB, Patel KB. Evaluation of Antidiabetic Drug Utilization Trends and Rationality of Prescriptions among Type 2 Diabetes Mellitus Patients in Outpatient Setting. International Journal of Life Sciences, Biotechnology and Pharma Research. 2025;14(4):1170-74 [URL]
4. Dhandia D, Jain S, Shukla VK, Sharma N, Yadav P, Arora S. International Council for Harmonization: Reception to Implementation. Understanding Pharmaceutical Standards and Regulations.1st ed. Routledge; 2025. p. 240-64. doi: 10.4324/9781003500971-15 [DOI:10.4324/9781003500971-15]
5. Vallejo JA, Colorado JA, Correa CH, Parra JE. Medical Ethics in Morphological Research. Inge CuC. 2025 May 13;21(1): 77-83. doi: 10.17981/ingecuc.21.1.2025.06 [DOI:10.17981/ingecuc.21.1.2025.06]
6. Mensah BT, Armah DNO, Narh IL, Annison L, Antwi-Baffour S. Association of Glycated Hemoglobin with Coagulation and Biochemical Profiles in Type II Diabetes Patients-a Case Control Study. 2024. doi: 10.21203/rs.3.rs-5320731/v1 [DOI:10.21203/rs.3.rs-5320731/v1]
7. Sundaresan M, Velmurugan G, Dhivakar M, Ramakrishnan A, Cherian M, Alexander T, et al. Gender Differential Prevalence of Overweight and Obesity, Hypertension and Diabetes in South India: A Population-Based Cross-Sectional Study. Glob Heart. 2024;19(1):72. doi: 10.5334/gh.1354 [DOI:10.5334/gh.1354] [PMID] [PMCID]
8. Solini A, Tricò D. Clinical efficacy and cost‐effectiveness of metformin in different patient populations: A narrative review of real‐world evidence. Diabetes Obes Metab. 2024; 26 Suppl 3:20-30. doi: 10.1111/dom.15729 [DOI:10.1111/dom.15729] [PMID]
9. Gupta R, Gaur K. Epidemiology of ischemic heart disease and diabetes in South Asia: an overview of the twin epidemic. Curr Diabetes Rev. 2021;17(9):e100620186664. doi: 10.2174/1573399816666201006144606 [DOI:10.2174/1573399816666201006144606] [PMID]
10. Safieddine B, Trachte F, Sperlich S, Epping J, Lange K, Geyer S. Trends of Antidiabetic and Cardiovascular Diseases Medication Prescriptions in Type 2 Diabetes between 2005 and 2017-A German Longitudinal Study Based on Claims Data. Int J Environ Res Public Health. 2023;20(5):4491. doi: 10.3390/ijerph20054491 [DOI:10.3390/ijerph20054491] [PMID] [PMCID]
11. Jha H, Khan TA, Khan N, Fatima G, DAS S. Analysis of Prescription Pattern of Anti-diabetic Medications in a Teaching Hospital in North India. Cureus. 2024;16(6) :e63343. doi: 10.7759/cureus.63343 [DOI:10.7759/cureus.63343]
12. Harding JL, Weber MB, Shaw JE. The global burden of diabetes. Textbook of diabetes. 6th ed. 2024. p.28-40. doi: 10.1002/9781119697473.ch3 [DOI:10.1002/9781119697473.ch3] [PMID] [PMCID]
13. Díez R, Cadenas R, Susperregui J, Sahagún AM, Fernández N, García JJ, et al. Drug-related problems and polypharmacy in nursing home residents: a cross-sectional study. Int J Environ Res Public Health. 2022;19(7):4313. doi: 10.3390/ijerph19074313 [DOI:10.3390/ijerph19074313] [PMID] [PMCID]
14. Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519-29. doi: 10.1016/S0140-6736(19)32131-2 [DOI:10.1016/S0140-6736(19)32131-2] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Contact Information
Address: Urmia University of Medical Sciences, Jahad Ave., Urmia, I.R. Iran. Post code: 57147-83734. P.O. Box. 1138
Email: ijrabms
gmail.com
rabmsumsu.ac.ir
Tel / Fax: +984431937235/+984432240642
